Mark Velleca
Net worth: 134 276 $ as of 30/09/2026
Net worth: 134 276 $ as of 30/09/2026
Dr. Mark A. Velleca is a Chairman, President & Chief Executive Officer at Black Diamond Therapeutics, Inc., a Chairman at Turbine Hálózatelemzo Kutatási Fejlesztési Kft.
and a Clinical Assistant Professor at Yale University.
He is on the Board of Directors at CREATE Medicines, Inc. (Massachusetts) and IMMvention Therapeutix, Inc. Dr. Velleca was previously employed as a Chairman by iOnctura SA, a Venture Partner by Hatteras Venture Partners, a President, Chief Executive Officer & Director by StrideBio, Inc., an Executive VP, Chief Policy & Advocacy Officer by Blood Cancer United, Inc., a Senior Vice President by CGI Pharmaceuticals, Inc., a Chairman by Turbine Simulated Cell Technologies Ltd., and a Principal by Yale-New Haven Hospital, Inc. He also served on the board at G1 Therapeutics, Inc., BioMarker Strategies LLC and Intellikine, Inc. He received his undergraduate degree from Yale University and a doctorate degree from the University of Washington.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 27/04/2026 | 71,234 ( 0.12% ) | 134 276 $ | 30/09/2026 |
| Companies | Position | Start |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Chief Executive Officer | 16/09/2023 |
Turbine Hálózatelemzo Kutatási Fejlesztési Kft.
Turbine Hálózatelemzo Kutatási Fejlesztési Kft. Packaged SoftwareTechnology Services Develops AI software which helps to find drugs for cancer | Chairman | 28/04/2021 |
Myeloid Therapeutics, Inc.
Myeloid Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutic drugs for the treatment of tumors and autoimmune diseases | Director/Board Member | - |
IMMvention Therapeutix, Inc.
IMMvention Therapeutix, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies | Director/Board Member | - |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| Companies | Position | End |
|---|---|---|
iOnctura SA
iOnctura SA BiotechnologyHealth Technology Develops therapies that extend health span for cancer patients | Chairman | 15/10/2026 |
| G1 THERAPEUTICS, INC. | Chief Executive Officer | 01/01/2021 |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners invests in companies located in the United States. The firm targets companies operating in the fields of biopharmaceuticals, medical devices, diagnostics, healthcare IT and human medicine. It provides financing for seed and early stage capital requirements and also makes co-investments. | Corporate Officer/Principal | 01/02/2023 |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Develops gene therapies | Chief Executive Officer | 01/01/2023 |
| ░░░ ░░░░░░░░ ░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 16 |
|---|---|
BioMarker Strategies LLC
BioMarker Strategies LLC Pharmaceuticals: GenericHealth Technology Develops medicines for cancer | Health Technology |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gilead Connecticut, Inc.
Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals and biotechnology chemicals | Health Technology |
Yale-New Haven Hospital, Inc.
Yale-New Haven Hospital, Inc. Hospital/Nursing ManagementHealth Services Provides health care services and medical courses | Health Services |
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit organization dedicated to funding research, education and support services for all blood cancers | Commercial Services |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners invests in companies located in the United States. The firm targets companies operating in the fields of biopharmaceuticals, medical devices, diagnostics, healthcare IT and human medicine. It provides financing for seed and early stage capital requirements and also makes co-investments. | Finance |
Intellikine LLC
Intellikine LLC Pharmaceuticals: MajorHealth Technology Develops and manufactures small molecule drugs for the treatment of cancer | Health Technology |
G1 Therapeutics, Inc.
G1 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cancer treatment | Health Technology |
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Develops gene therapies | Health Technology |
iOnctura SA
iOnctura SA BiotechnologyHealth Technology Develops therapies that extend health span for cancer patients | Health Technology |
Turbine Hálózatelemzo Kutatási Fejlesztési Kft.
Turbine Hálózatelemzo Kutatási Fejlesztési Kft. Packaged SoftwareTechnology Services Develops AI software which helps to find drugs for cancer | Technology Services |
Myeloid Therapeutics, Inc.
Myeloid Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutic drugs for the treatment of tumors and autoimmune diseases | Health Technology |
IMMvention Therapeutix, Inc.
IMMvention Therapeutix, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies | Health Technology |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Packaged SoftwareTechnology Services Provides AI solutions to understand oncology patients with simulated cells | Technology Services |
Select your edition
All financial news and data tailored to specific country editions